Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.
Karl Ludwig-Kley Merck KGAA, and Rakesh Sachdev, Sigma-Aldrich president & CEO, discuss Merck's acquisition of Sigma-Aldrich and the future of life sciences and technology.
An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.
CNBC's Meg Tirrell, and Scott Gottlieb, American Enterprise Institute, discuss the latest developments in controlling the Ebola epidemic.
U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.
Vamil Divan, Senior Analyst, U.S. Pharmaceuticals at Credit Suisse, discusses news that Bristol-Myers Squibb and Ono Pharmaceutical are suing Merck over the Keytruda cancer drug.
CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.
CNBC's Andrea Day reports on a former convicted drug smuggler who has turned to selling diet supplements.
Infinity Pharma will receive $275 million upfront from AbbVie, as part of a new venture to develop blood cancer treatments. Infinity CEO Adelene Q. Perkins, explains the significance of the deal, with CNBC's Meg Tirrell.
CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.
Kite Pharma is working on a treatment which involves taking a cancer patient's own t-cells out of their body, genetically modifying them to better target cancer, and then re-administering them. Its CEO Arie Belldegrun, provides insight to the positive study with the therapy.
Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.
CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.
CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.
Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.
The first British citizen confirmed to be infected with the deadly Ebola disease is being evacuated from Sierra Leone.
CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."
Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.
Obesity has big potential for drug makers. CNBC's Meg Tirrell examines why physicians have been cautious to adopt new diet drugs.
CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.